Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Cassiopea S.p.A.
  6. News
  7. Summary
    SKIN   IT0005108359


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

EQS-Adhoc: Cassiopea Announces Results for First Half of 2021

07/29/2021 | 01:02am EDT
EQS Group-Ad-hoc: Cassiopea S.p.A. / Key word(s): Half Year Results 
Cassiopea Announces Results for First Half of 2021 
29-Jul-2021 / 07:00 CET/CEST 
Release of an ad hoc announcement pursuant to Art. 53 LR 
The issuer is solely responsible for the content of this announcement. 
Ad hoc announcement pursuant to Art. 53 LR 
Lainate, Italy - July 29, 2021 - Cassiopea SpA (SIX: SKIN), a specialty pharmaceutical company developing and preparing 
to commercialize prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential 
dermatological conditions, today announced half-year results for the period ended 30 June 2021. 
Key Highlights 
  . During the first half of 2021, activities were focused on the preparations for the US commercial launch of Winlevi 
    (R) (clascoterone cream 1 %) and advancing the development of clascoterone solution for androgenetic alopecia 
  . Multiple transaction structures and opportunities were evaluated over the last twelve months in order to optimize 
    the US commercial launch of Winlevi(R). 
  . Post period, on July 26, Cassiopea and Sun Pharmaceuticals Industries Ltd. announced the signing of License and 
    Supply Agreements for Winlevi(R) (clascoterone cream 1%) in the US and Canada. Under terms of the agreements, Sun 
    Pharma will commercialize Winlevi(R) in the US and Canada and Cassiopea will be the exclusive supplier of the 
    product. Cassiopea will receive an upfront payment of US USD45 million, potential commercial milestones totalling up 
    to US USD190 million and customary double digit royalties. The agreements will close upon the expiration of HSR 
    waiting period. Winlevi(R) is expected to be available in the US in Q4 2021. 
  . The Phase II trial investigating clascoterone solution for the treatment of androgenetic alopecia (AGA) in females 
    was completed in the reporting period. Top line results will be available in 3Q 2021. 
  . Progress was made in the development of a new Patient Reported Outcome (PRO) Questionnaire for AGA which has been 
    requested by the FDA to be used in the future Phase III trials of clascoterone solution for AGA in males. 
Diana Harbort, CEO of Cassiopea SpA, commented: 'The highlight of the year to date was the announcement on July 26 of 
the signing of License and Supply Agreements for Winlevi(R) in the US and Canada with Sun Pharmaceutical Industries 
Ltd. We are very pleased to partner with Sun Pharma. Sun Pharma has a strong established US dermatology presence and 
will make Winlevi(R) widely available to dermatology health care providers and their patients. Following this 
transaction, Cassiopea will be expecting substantial revenue streams for the foreseeable future and will be well funded 
to continue the development of its innovative dermatology pipeline. Until the end of 2021, our priorities are 
supporting Sun Pharma in the successful launch of Winlevi(R) and the continuing the development of clascoterone 
solution for AGA, an area that has not seen innovation in 20-30 years. We estimate that Cassiopea will become 
profitable in 2021 with revenues in the range of EUR 37-39 million and operating profit in the range of EUR 24-28 
Key financial figures 
In EUR thousands                               H1 2021    H1 2020 
(with the exception of the share data in EUR) 
Revenue                                        -          - 
Cost of sales                                  -          - 
Research and development expenses              (3,753)    (2,510) 
Selling, general and administrative expenses   (2,535)    (2,180) 
Net operating expenses                         (6,288)    (4,690) 
Operating result                               (6,288)    (4,690) 
Profit (Loss) before taxes                     (6,165)    (5,322) 
Profit (Loss) after taxes for the period       (6,165)    (5,322) 
Profit (Loss) per share                        -0.573     -0.53 
In EUR thousands                               30.06.2021 31.12.2020 
Non-current assets                             12,498     12,797 
Inventories                                    1,817      761 
Other current assets                           2,291      2,423 
Cash and cash equivalents                      1,796      2,646 
Total assets                                   18,402     18,627 
Non-current liabilities                        -          66 
Current Liabilities                            8,557      2,946 
Total Equity                                   9,845      15,615 
Total Equity & Liabilities                     18,402     18,627 

Financial Results for the Half Year Ended June 30, 2021 . No revenues and consequently no cost of sales were generated in H1 2021 since no products were on the market. . R&D costs increased mainly due to Phase II trials of Clascoterone solution for androgenetic alopecia in females. . SG&A in line with the same period of the previous year. . Loss for the period increase from EUR 5,322 thousand to EUR 6,165 thousand. . Non-current assets, which include intangible and the R&D credit, stable at EUR 12,498 thousand. . Inventories, EUR 1,817 thousand, refer to the API (Active Principle Ingredient) stock required for the production

for the commercial launch of Winlevi(R). . Current liabilities include EUR 6,226 thousand related to the draw down from the Cosmo Pharmaceuticals N.V.

unsecured credit facility (EUR 6,000 thousand) and interest, that will be reimbursed in the course of the following

months. . Total equity decreased from EUR 15,615 thousand to EUR 9,845 thousand mainly because of the loss for the period. Half Year 2021 results conference call at 16:00 CEST on July 29, 2021 Diana Harbort, CEO; Luigi Moro, CSO; Alessandro Mazzetti, CMO; Pierpaolo Guzzo, CFO; and Marco Lecchi, Finance Director, will host a conference call to discuss the half year 2021 financial results to be held today at 16:00 CEST. Dial-in numbers:

Switzerland / Europe: +41 (0) 58 310 50 00 
From UK:              +44 (0) 207 107 06 13 
From USA:             +1 (1) 631 570 56 13 The Half-Year Report 2021 and the presentation with further information were published today, July 29, 2021, at 7:00 am CEST, and are available for download at: https://www.cassiopea.com/wp-content/uploads/2021/07/Cassiopea_Half_Year_Report_2021.pdf and https://www.cassiopea.com/wp-content/uploads/2021/07/Cassiopea_Half_Year_2021-Financial-Results_Presentation.pdf 

Next events

Credit Suisse Equity Conference          November 16-19, 2021, Zurich 
Jefferies Global Health Care Conference  November 16-18, 2021, London 

About Winlevi


Winlevi^(R) (clascoterone cream 1%), is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. See www.WINLEVI.com for complete prescribing information and important safety information.

Important Safety Information


WARNINGS Local Irritation: Pruritus, burning, skin redness or peeling may be experienced with WINLEVI cream. If these effects occur, discontinue or reduce the frequency of application of WINLEVI cream.

Hypothalamic-pituitary-adrenal (HPA) axis suppression may occur during or after treatment with WINLEVI. In the PK trial, HPA axis suppression was observed in 1/20 (5%) of adult subjects and 2/22 (9%) of adolescent subjects at Day 14. All subjects returned to normal HPA axis function at follow-up 4 weeks after stopping treatment. Conditions which augment systemic absorption include use over large surface areas, prolonged use, and the use of occlusive dressings. Attempt to withdraw use if HPA axis suppression develops.

Pediatric patients may be more susceptible to systemic toxicity.

Hyperkalemia: Elevated potassium levels were observed in some subjects during the clinical trials. Shifts from normal to elevated potassium levels were observed in 5% of WINLEVI-treated subjects and 4% of vehicle-treated subjects.

ADVERSE REACTIONS Most common adverse reactions occurring in 7 to 12% of patients are erythema/reddening, pruritus and scaling/dryness. Additionally, edema, stinging, and burning occurred in >3% of patients and were reported in a similar percentage of subjects treated with vehicle.

About Cassiopea

Cassiopea is a specialty pharmaceutical company developing and commercializing prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological conditions, particularly acne, androgenetic alopecia (or AGA) and genital warts. Cassiopea is investing in innovation that is driving scientific advancement in areas that have been largely ignored for decades. The portfolio comprises four unencumbered clinical candidates, for which Cassiopea owns the worldwide rights. The Company's strategy is to leverage this expertise to optimize the commercial potential for its products directly or with a partner. For further information on Cassiopea, please visit www.cassiopea.com.

Contact Cassiopea SpA Diana Harbort, CEO & Head of Investor Relations Tel: +39 02 868 911 24, dharbort@cassiopea.com

(MORE TO FOLLOW) Dow Jones Newswires

July 29, 2021 01:01 ET (05:01 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
CASSIOPEA S.P.A. 0.91% 33.1 Delayed Quote.-31.75%
COSMO PHARMACEUTICALS N.V. 1.13% 71.8 Delayed Quote.-15.53%
DJ INDUSTRIAL 1.09% 35294.76 Delayed Quote.14.07%
SUN PHARMACEUTICAL INDUSTRIES LTD. -0.15% 841.3 Delayed Quote.42.03%
All news about CASSIOPEA S.P.A.
10/04COSMO PHARMACEUTICALS N : Initiates Public Exchange Offer For Cassiopea
10/04CASSIOPEA S P A : Cosmo pharmaceuticals n.v. launchesápublic exchange offer to acquire cas..
10/04Cosmo pharmaceuticals n.v. launches -2-
10/04Cosmo pharmaceuticals n.v. launches public exchange offer to acquire cassiopea s.p.a.
10/04Cosmo Pharmaceuticals Intends to Acquire Cassiopea
10/04Cosmo Pharmaceuticals N.V. made an offer to acquire remaining 53.4% stake in Cassiopea ..
09/13CASSIOPEA S P A : Public Investor Presentation H.C. Wainwright Annual Global Conference
09/10CASSIOPEA S P A : Female Androgenetic Alopecia Treatment Shows Improvement in Mid-Stage Tr..
09/10EQS-ADHOC : Cassiopea SpA Announces Topline Results of Phase II Proof of Concept Trial of ..
09/10Cassiopea SpA Announces Topline Results of Phase II Proof of Concept Trial of Clascoter..
More news
Sales 2021 38,8 M 45,0 M 45,0 M
Net income 2021 25,0 M 29,0 M 29,0 M
Net cash 2021 29,7 M 34,5 M 34,5 M
P/E ratio 2021 13,1x
Yield 2021 -
Capitalization 332 M 385 M 385 M
EV / Sales 2021 7,80x
EV / Sales 2022 18,5x
Nbr of Employees 11
Free-Float 41,2%
Duration : Period :
Cassiopea S.p.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CASSIOPEA S.P.A.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 30,90 €
Average target price 47,94 €
Spread / Average Target 55,1%
EPS Revisions
Managers and Directors
Diana Harbort Chief Executive Officer & Executive Director
Pierpaolo Guzzo Chairman & Chief Financial Officer
Luigi Moro Chief Scientific Officer
Alessandro Mazzetti Chief Medical Officer
Martina Cartwright Senior Director-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
CASSIOPEA S.P.A.-31.75%385
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820